Elise Chong, MD, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Elise Chong, MD
Advertisement
Articles by Elise Chong, MD
Advertisement
Latest Updated Articles
Assessing the Durability and Toxicity of CAR T-Cell Therapy in DLBCLPublished: January 17th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
